Last reviewed · How we verify
Albumin-bound Paclitaxone
Albumin binding enhances the solubility of paclitaxel, allowing for higher doses to be administered.
Albumin binding enhances the solubility of paclitaxel, allowing for higher doses to be administered. Used for Non-small cell lung cancer, Breast cancer, Ovarian cancer.
At a glance
| Generic name | Albumin-bound Paclitaxone |
|---|---|
| Sponsor | RemeGen Co., Ltd. |
| Drug class | Taxane |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Paclitaxel is a microtubule inhibitor that disrupts cell division, leading to cell death. Albumin binding increases the solubility of paclitaxel, enabling higher doses to be administered, which can improve efficacy.
Approved indications
- Non-small cell lung cancer
- Breast cancer
- Ovarian cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |